EMPA-REG OUTCOME: First study whch showed cardiovascular risk reduction in type 2 diabetic patients

Abstract

In the EMPA-REG study a 30% reduction of cardiovascular mortality was observed. Empagliflozin is the first antidiabetic drug, where this effect was observed.

Keywords

• Cardiovascular risk
• gliflozines
• diabetes type 2